Pre-made Glenzocimab benchmark antibody ( Fab, anti-GP6 therapeutic antibody, Anti-BDPLT11/GPIV/GPVI Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-247
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Glenzocimab biosimilar, Fab, Anti-GP6 Antibody: Anti-BDPLT11/GPIV/GPVI therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Glenzocimab biosimilar, Fab, Anti-GP6 Antibody: Anti-BDPLT11/GPIV/GPVI therapeutic antibody |
|---|---|
| INN Name | Glenzocimab |
| Target | GP6 |
| Format | Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Acticor Biotech |
| Conditions Approved | NA |
| Conditions Active | Stroke,COVID-19 |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | GP6 |
| Package |
Previous slide
Next slide
